Radiopharm Theranostics (ASX:RAD) and AtomVie Global Radiopharma partnered with Radiopharm Ventures to develop and manufacture the 177Lu-BetaBart radio-antibody for treating solid tumors, according to a Wednesday filing with the Australian Securities Exchange.
The first-in-human therapeutic trial with 177Lu-BetaBart is set to start in the US in 2025, the filing said.
Radiopharm Ventures is a joint venture between Radiopharm Theranostics and MD Anderson Cancer Center in Texas, according to the filing.
Shares of Radiopharm Theranostics rose nearly 4% in midday trade.
Price (AUD): $0.03, Change: $+0.0010, Percent Change: +3.85%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。